文献速递脊柱关节炎其他结缔组织病

西班牙脊柱关节炎住院患者淀粉样变性17年趋势研究

Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999-2015)-TREND-EspA study.
PubMed 文献 · RMD Open · 2021-01-01

基于西班牙全国住院登记1999–2015年的观察性回顾性匹配队列研究,分析脊柱关节炎(SpA)患者中淀粉样变性的发生率及趋势。SpA队列淀粉样变性发生率为0.7%,非SpA队列为0.1%(p<0.001),SpA队列发生率总体每年下降4.63%,而非SpA队列每年上升10.25%。淀粉样变性与所有SpA类型均强相关(AOR 10.4),其中与SpA-IBD关联最强(AOR 22.9)。

要点

  • SpA患者淀粉样变性发生率0.7%,显著高于非SpA患者的0.1%。
  • 1999–2015年SpA队列淀粉样变性发生率每年下降4.63%,非SpA队列每年上升10.25%。
  • SpA-IBD与淀粉样变性关联最强(AOR 22.9),AS、PsA和ReA的AOR约为10。

核心结论

  • 西班牙SpA患者中淀粉样变性发生率在研究期间大幅下降。
  • 淀粉样变性与SpA-IBD关联最强,与PsA和ReA的关联强度与AS相似。

研究设计与样本

  • 观察性回顾性基于人群的匹配队列研究,分析1999–2015年西班牙全国住院登记中SpA患者(包括AS、PsA、SpA-IBD和ReA)的所有住院记录,并选取按年龄、性别和入院年份匹配的对照组。

主要发现

  • 研究数据库每组包含107 140例次住院数据。
  • SpA队列中792例(占所有住院的0.7%)诊断为淀粉样变性,非SpA队列中68例(0.1%),p<0.001。
  • 1999–2015年SpA队列淀粉样变性发生率总体每年下降4.63%,非SpA队列每年上升10.25%。
  • 淀粉样变性与所有SpA的AOR为10.4(95% CI 8.2–13.3)。

临床怎么用

  • 在SpA患者中,尤其合并炎症性肠病者,应警惕淀粉样变性可能,尽管其发生率呈下降趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the incidence of amyloidosis and trends therein in patients with spondyloarthritis (SpA) over a long period (17 years). METHODS: An observational retrospective population-based matched cohort study was conducted. All the admissions of patients with SpA, including ankylosing spondylitis (AS), psoriatic arthritis (PsA), arthritis associated with inflammatory bowel disease (SpA-IBD) and reactive arthritis (ReA), reported between 1999 and 2015, were analysed and a control group matched by age, sex and year of admission was selected. Incidence rates for amyloidosis were calculated. Generalised linear models were used for trend analysis and unconditional logistic regression for calculating crude and adjusted ORs (AOR) to assess the association between amyloidosis and SpA. RESULTS: The study database contained data on 107 140 admissions in each group. Between 1999 and 2015, 792 patients in the SpA cohort (0.7% of all admissions) had a diagnosis of amyloidosis versus 68 in the non-SpA cohort (0.1%) (p<0.001). From 1999 to 2015, incidence rates of amyloidosis tended to decrease in the SpA cohort (-4.63%/year overall), while they increased in the Non-SpA cohort (+10.25%/year overall). We found strong associations of amyloidosis with all SpAs (AOR 10.4; 95% CI 8.2 to 13.3) and with each type studied (AORs 10.05 (7.84 to 12. 88) for AS, 9.5 (7.3 to 12.4) for PsA, 22.9 (16.6 to 31.7) for SpA-IBD and 10.1 (6.1 to 16.7) for ReA). CONCLUSIONS: Incidence of amyloidosis among patients with SpA has strongly decreased in Spain. Amyloidosis is most strongly associated with SpA-IBD while the strength of association with PsA and ReA is similar to that with AS.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Mazzucchelli R, Almodovar-González R, Dieguez-Costa E, et al. Trends in amyloidosis in spondyloarthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999-2015)-TREND-EspA study. RMD Open. 2021. PMID: 34593628. doi:10.1136/rmdopen-2021-001782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。